Barclays
CRL icon

Barclays’s Charles River Laboratories CRL Stock Holding History

Barclays’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,000
Closed -$980K – 5239
2023
Q3 		$980K Buy
+5,000
New +$1.03M ﹤0.01% 2355
2014
Q3 		– Sell
-100
Closed -$5K – 7670
2014
Q2 		$5K Hold
100
– – ﹤0.01% 7107
2014
Q1 		$6K Buy
+100
New +$5.83K ﹤0.01% 7128
2013
Q4 		– Sell
-50,000
Closed -$2.3M – 7545
2013
Q3 		$2.3M Buy
+50,000
New +$2.29M ﹤0.01% 2413

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Barclays's CRL Position: Q2 2026 in Review

Barclays reduced its Charles River Laboratories (CRL) stake by 77% in Q2 2026, selling an estimated $32.2M and leaving 53,896 shares worth $12.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1378.

Barclays first reported a position in CRL in Q2 2013 and has held it in 51 quarters since. The position peaked at $40.5M in Q1 2026. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Barclays held 53,896 shares of Charles River Laboratories worth $12.2M as of Q2 2026.
  • Barclays sold 181,040 Charles River Laboratories shares in Q2 2026, an estimated $32.2M.
  • Charles River Laboratories made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1378 holding.
  • Barclays first reported a position in Charles River Laboratories in Q2 2013 and has held it in 51 quarters since.
  • Barclays's Charles River Laboratories position peaked at $40.5M in Q1 2026.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.